Abstract: A light applicator (5) for examining and/or treating an organic body includes a minimal-invasive, rigid, semi-flexible or flexible insertion section (11) which extends along a longitudinal direction (L) and at its distal end includes an LED (19). The light applicator (5) includes a first electrical lead (61a) for the supply of electricity to the LED (19). The lead extends in the insertion section (11) in the longitudinal direction (L) and there has a cross-sectional area of at least 70% of the cross-sectional area of the light applicator (5). The light applicator (5) in the insertion section (11) is thermally insulated in the radial direction in a manner such that the radial thermal insulation reduces proximally.

Abstract: Prostate cancer is the most prevalent solid cancer among men in Western Countries. The clinical behavior of localized prostate cancer is highly variable. Hence, there is a high clinical need for precise biomarkers for identification of aggressive disease in addition to established clinical parameters. The present invention relates to a prognostic multi-gene expression score based on transcriptome-wide gene expression analysis providing a method for calculating a score (ProstaTrend score) that allows the prediction of death of disease (DoD) and/or biochemical recurrence (BCR), long-term prognosis and outcome of prostate cancer patients. The present invention is an independent predictor of prognosis and is suitable for the identification of high-risk patients among patients with a clinical classification of low or intermediate risk prior and after surgery, such as radical prostatectomy.

Abstract: A light applicator (5) for examining and/or treating an organic body includes a minimal-invasive, rigid, semi-flexible or flexible insertion section (11) which extends along a longitudinal direction (L) and at its distal end includes an LED (19). The light applicator (5) includes a first electrical lead (61a) for the supply of electricity to the LED (19). The lead extends in the insertion section (11) in the longitudinal direction (L) and there has a cross-sectional area of at least 70% of the cross-sectional area of the light applicator (5). The light applicator (5) in the insertion section (11) is thermally insulated in the radial direction in a manner such that the radial thermal insulation reduces proximally.

Abstract: The invention relates to urinary catheters having a catheter tube with a first connection on the distal end and at least one catheter eye to be positioned in the urinary bladder. The urinary catheters are distinguished in particular in that they may be used problem-free as indwelling catheters. To this end, disposed in the urinary bladder is a reservoir container that is connected via a channel running parallel to the catheter tube to a second connection as distal end of the channel. In addition, the channel is connected to the urethra via at least one opening of the channel wall.

Abstract: Urinary catheters comprising a tube having an opening at the distal end, and at least one catheter eye that is to be positioned in the bladder, the tube comprising at least one wall region that can be inflated or filled relative to a wall region of the tube. The catheters can be used as permanent catheters that are retained securely in the bladder and completely empty said bladder. The urinary catheter consists of a plurality of layers that are applied in succession and are made of a rubber-like material. The wall region is at least one wall region of the tube, the wall region being at least two mutually separate layers made of the rubber-like material of the wall region. A component of the wall of the tube is at least one channel for inflating or filling or cleaning the wall region, so that the tube is integral.

Abstract: The invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumor cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer. Clinical application of assays based on these biomarker help reduce the high number of false positives of current standard screening assays.

Abstract: The invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumor cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer. Clinical application of assays based on these biomarker help reduce the high number of false positives of current standard screening assays.

Abstract: The invention relates to urinary catheters having a catheter tube with a first connection on the distal end and at least one catheter eye to be positioned in the urinary bladder. The urinary catheters are distinguished in particular in that they may be used problem-free as indwelling catheters. To this end, disposed in the urinary bladder is a reservoir container that is connected via a channel running parallel to the catheter tube to a second connection as distal end of the channel. In addition, the channel is connected to the urethra via at least one opening of the channel wall.

Abstract: The invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumour cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer. Clinical application of assays based on these biomarker help reduce the high number of false positives of current standard screening assays.

Abstract: The invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumour cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer. Clinical application of assays based on these biomarker help reduce the high number of false positives of current standard screening assays.

Abstract: The invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumour cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer. Clinical application of assays based on these biomarker help reduce the high number of false positives of current standard screening assays.

Abstract: The invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumour cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer. Clinical application of assays based on these biomarker help reduce the high number of false positives of current standard screening assays.

Abstract: The invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumour cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer. Clinical application of assays based on these biomarker help reduce the high number of false positives of current standard screening assays.

Abstract: The invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumour cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer. Clinical application of assays based on these biomarker help reduce the high number of false positives of current standard screening assays.

Abstract: The invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumour cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer. Clinical application of assays based on these biomarker help reduce the high number of false positives of current standard screening assays.

Abstract: The invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumour cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer. Clinical application of assays based on these biomarker help reduce the high number of false positives of current standard screening assays.

Abstract: The invention provides a process for generating an avian cell line of duck origin by a process comprising: —cultivating embryonic avian cells in cell culture medium, preferably comprising fetal calf serum (FBS) for more than 40 passages while reducing the concentration of FBS to 1-2% vol/vol FBS, —transferring passaged cells into cell culture medium having 0% FBS, —resulting in the generation of a non-embryonic avian cell line suitable for non-adherent growth, i.e. for growth in suspended culture.

Abstract: The present invention relates on a non-invasive method for diagnosing prostate cancer and/or assessing the risk of a subject acquiring prostate cancer comprising the analysis of the expression of the marker gene hepsin in an urine sample. It further relates on a non-invasive method for diagnosing prostate cancer and/or assessing the risk of a subject acquiring prostate cancer by determining the expression levels of the marker genes hepsin, EZH2, prostein and PCA3.

Abstract: A supporting and drive belt including a belt body or sheathing which encloses tensile carriers. The running surface of the belt can be flat and parallel to the belt back or have trapezium-shaped or semicircular ribs and grooves, wherein the profile of a drive pulley or of a deflecting pulley is approximately complementary to the running surface of the belt. One or more tensile carriers are provided for each rib, wherein the tensile carriers are laid or stranded alternately in the “Z” direction and the “S” direction.

Abstract: The present invention relates on a non-invasive method for diagnosing prostate cancer and/or assessing the risk of a subject acquiring prostate cancer comprising the analysis of the expression of the marker gene hepsin in an urine sample. It further relates on a non-invasive method for diagnosing prostate cancer and/or assessing the risk of a subject acquiring prostate cancer by determining the expression levels of the marker genes hepsin, EZH2, prostein and PCA3.